Disappointing Phase III Data for Avicena Drug Candidate
Posted on: Wednesday, 10 May 2006, 12:08 CDT
US biotech company Avicena's drug candidate ALS-02 has generated disappointing results in a phase III trial evaluating the drug in the treatment of the neurodegenerative disease amyotrophic lateral sclerosis, or Lou Gehrig's disease.
Study data showed no statistically significant difference between ALS-02 5g per day and placebo with regard to the study's primary and secondary endpoints, which consisted of various measures of muscle strength, muscle fatigue and functional scores.
However, in a separate analysis when mortality data was combined and analyzed with mortality data from a second study of ALS-02, the analysis demonstrated a positive trend toward decreased mortality in subjects receiving the compound. The compound was also found to be safe and well tolerated by patients.
"We are hopeful that together with FDA we will be able to identify a clear path to market for ALS-02," stated Dr Belinda Tsao-Nivaggioli, chief executive officer of Avicena. "It is important to note that the one currently approved treatment for patients suffering from ALS offers only limited, short-term survival benefit and has not demonstrated benefit in regard to measures of muscle strength and neurological function."
Avicena's phase III study of ALS-02 was a multi-center, double-blind, placebo-controlled, randomized trial designed to evaluate the safety and efficacy of the compound at a dose of 5g per day for nine months.
Source: Datamonitor
Related Articles
- Clinical Phase I Study Report of Marshall Edwards' Compound Triphendiol to Be Reported in ASCO Proceedings
- USPTO Issues Patent for Avicena Group's Proprietary Compounds to Treat Amyotrophic Lateral Sclerosis
- Icagen Announces Initiation of Phase I Study of ICA-105665, a Novel Compound for the Treatment of Epilepsy
- NIH Study Tests Avicena Parkinson's Drug
- Theravance Announces Results From Preclinical Research and Phase 1 Clinical Studies With Investigational Gastrointestinal Motility Compound Presented at 2007 Digestive Disease Week
- Investigators Report New Renal, Mortality and Safety Data From NAPA Trial of NATRECOR(R) (Nesiritide)
- Clinical Study Shows Avicena's Nurigene(TM) Significantly Increases Skin Firmness and Elasticity
- Arena Pharmaceuticals Presents Favorable Results From Phase 1 Studies of APD125, a Novel Insomnia Compound
- Study Shows That MedMined Data Mining Surveillance(R) Helps Detect and Reduce Blood Culture Contamination; Results to Be Presented at 2006 APIC Conference
- Promising Study for Avicena's Huntington's Drug
 |
 |
User Comments (0)
RSS Feeds